Advertisement

Die Bedeutung von Neuroleptika der neueren Generation in der Therapie schizophrener Patienten mit Minussymptomatik

  • F. Müller-Spahn

Zusammenfassung

1952 wurde von den französischen Psychiatern Delay and Deniker erstmals der günstige klinische Effekt von Chlorpromazin in der Behandlung manischer und schizophrener Psychosen beschrieben. In den folgenden Jahrzehnten wurde eine kaum übersehbare Anzahl neuer antipsychotisch wirksamer Substanzen mit z. T. sehr unterschiedlicher chemischer Struktur entwickelt. Pharmakologisch gemeinsam ist allen diesen Verbindungen die Blockade dopaminerger Rezeptoren im ZNS. Dieses Wirkprinzip führte zur Formulierung der Dopamin-Hypothese, die eine funktioneile Überaktivität dopaminerger Rezeptoren im Zusammenhang mit dem Auftreten produktiv psychotischer Symptome postulierte.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andreasen NC, Smith MR, Jacoby CG et al. (1982) Ventricular enlargement in schizophrenia: definition and prevalence. Am J Psychiatry 139: 292–296.PubMedGoogle Scholar
  2. Angrist B, Peselow E, Rubinstein M et al. (1982) Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 78: 128–130.PubMedCrossRefGoogle Scholar
  3. Bersani G, Bressa G, Meco G, Marini S, Pozzi F (1990) Combined serotonin 5-HT-2 und dopamine-D-2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with Risperidone (R 64 766). Hum Psychopharmacol (im Druck).Google Scholar
  4. Boyer P (1983) Evaluation of the desinhibitory effect of some neuroleptics at low doses in controlled trials. Comm. VII World Congress of Psychiatry, Wien 1983.Google Scholar
  5. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452.PubMedGoogle Scholar
  6. Castelao F, Ferreira F, Glders Y, Heylen S (1990) Risperidone (R 64 766) in the treatment of therapy — resistant chronic psychotic patients: an open dose — finding study. Schizophr Res (im Druck).Google Scholar
  7. Christensson E, Björk A, Gustavsson B (1985) Amperozide, a novel psychotropic compound with specific effect on limbic brain areas. Acta Physiol Scand 124 (Suppl 542): 281.Google Scholar
  8. Claghorn J, Honigfeld G, Abuzzahab P, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384.PubMedCrossRefGoogle Scholar
  9. Crow TJ (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 280: 66–68.PubMedCrossRefGoogle Scholar
  10. Delay J, Deniker P (1952) 38 cas de psychoses traités par la cure prolongée et continué de 4568 R.P. Ann Med Psychol 110: 364.Google Scholar
  11. Dieterle D, Ackenheil M, Müller-Spahn F, Kapfhammer H-P. (1987) Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 20: 52–57.PubMedCrossRefGoogle Scholar
  12. Dieterle D, Müller-Spahn F, Ackenheil M (1988) Comparison of zotepine and perazine in schizophrenia. Psychopharmacology 96 (Suppl: 340.Google Scholar
  13. Falloon F, Watt DC, Shepherd M (1978) The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: Pimozide vs fluphenazine. Psychol Med 8: 265–274.PubMedCrossRefGoogle Scholar
  14. Feinberg S, Kay S, Elijovich L, Fiszbein A, Opler L (1988) Pimozide treatment of the negative schizophrenic syndrome: an open trial. J Clin Psychiatry 49(6): 235–241.PubMedGoogle Scholar
  15. Gerlach J, Luchdorf K (1975) The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacologia 44: 105–110.PubMedCrossRefGoogle Scholar
  16. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456.PubMedGoogle Scholar
  17. Jackson JH (1884) Remarks on evolution and dissolution of the nervous system. Journal of Mental Science 33: 25–48.Google Scholar
  18. Janssen P, Niemegeers C, Awouters F, Schellekens K, Megens A, Meert T (1988) Risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693.PubMedGoogle Scholar
  19. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.PubMedCrossRefGoogle Scholar
  20. Kolakowska T, Williams AD, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome. In: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146: 229–246.PubMedCrossRefGoogle Scholar
  21. Mackay A (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 379–386.PubMedCrossRefGoogle Scholar
  22. Meltzer HY Zureick J (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 68–77.Google Scholar
  23. Müller-Spahn F, Botschev C, Dieterle D (1990) Efficacy and tolerability of Risperidone, a serotonine-S-2-and dopamine-D-2-receptor antagonist, in the treatment of chronic schizophrenic patients. 17 th Congress of CINP, Kyoto 1990.Google Scholar
  24. Naber D, Dieterle D (1989) Efficacy and tolerability of SDZ HDC 912, a dopamine D-2 agonist, in the treatment of schizophrenia. Meeting in Rouffach 1989.Google Scholar
  25. Niemegeers CJE (1988) Pharmakologie und Biochemie niedrig dosierter Neuroleptika. In: Hippins H, Laakmann G (Hrsg) Therapie mit Neuroleptika-Niedrigdosierung. Perimed, Erlangen, pp 10–18.Google Scholar
  26. Pinder RM, Brogden RN, Sawyer PR et al. (1976) Pimozide, a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 12: 1–40.PubMedCrossRefGoogle Scholar
  27. Puech AJ, Simon P (1983) Do neuroleptics which improve “minus symptomatology” of schizophrenia have a specific pharmacological profile? Comm. VII World Congress of Psychiatry 1983.Google Scholar
  28. Reyntjens A, Gelders YG, Hoppenbrouwers M, M-LJA Vanden Bussche G (1986) Thymosthenic effects of Ritanserin (R 55 667), a centrally acting serotonin-S-2-receptor blocker. Drug Dev Res 8: 205–211.CrossRefGoogle Scholar
  29. Wachtel H, Dorow R (1983) Dual action, a central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci 32: 421–432.PubMedCrossRefGoogle Scholar
  30. Wetzel H, Benkert O (1989) Neuroleptika: Neue Substanzen — Neue Indikationen. In: Herz A, Hippins H, Spann W (Hrsg) Psychopharmaka heute. Springer, Berlin Heidelberg New York Tokyo, S 108–128.Google Scholar
  31. Wiedemann K, Benkert O, Holsboer F (1989) B-HT 920 — a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry (im Druck).Google Scholar
  32. Wiesel F, Alfredsson G, Bjerkenstedt L, Härnryd C, Oxenstierna G, Sedvall G (1985) Le dogmatil dans le traitement des symptômes negatifs chez des patients schizophrènes. Sem Hóp Paris 61(19): 1317–1321.Google Scholar
  33. Wilson LG, Roberts RW, Gerber CJ et al. (1982) Pimozide versus chlorpromazine in chromc schizophrenia: a 52 week double-blind study of maintenance therapy. J Clin Psychiatry 43: 62–65.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • F. Müller-Spahn

There are no affiliations available

Personalised recommendations